ClinicalTrials.gg
CompletedNCT00835276Updated Aug 20, 2009Results posted

Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

A Phase 1 interventional study of Fexofenadine 180 mg tablets and ALLEGRA® 180 mg tablets in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-20.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will compare the relative bioavailability (rate and extent of absorption) of 180 mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd. with that of 180 mg ALLEGRA® Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 180 mg tablet) in healthy adult volunteers under fasting conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All volunteers selected for this study will be healthy, non-smoking men and women 18 to 55 years of age, inclusive, at the time of dosing. The volunteer's (BMI) is less that or equal to 30.
  • If female and :

    • of child bearing potential, is practicing an acceptable method of for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence; or
    • is for at least 1 year; or
    • is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

Exclusion criteria

Exclusion Criteria:

  • Volunteers with a recent history of drug or alcohol addiction or abuse.
  • Volunteers with the presence of a disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators).
  • Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
  • Volunteers demonstration a positive surface antigen screen, antibody screen or a reactive antibody screen.
  • Volunteers demonstrating a positive drug abuse screen when screened for this study.
  • Female volunteers who are currently breast feeding.
  • Female volunteers who are demonstrating a positive pregnancy screen.
  • Volunteers with a history of allergic response(s) to fexofenadine or related drugs.
  • Volunteers with a history of clinically significant allergies including drug allergies.
  • Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
  • Volunteers who currently use or reports using tobacco or nicotine-containing products within 90 days prior to Period I dosing.
  • Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to Period I dosing.
  • Volunteers who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will by advised not to donate blood for four weeks after completing the study.
  • Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
  • Volunteers who report receiving any drug within 30 days prior to Period I dosing.
  • Volunteers who report taking any prescription medication in the 14 days prior to Period I dosing, with the exception of topical products without systemic absorption.
  • Volunteers who have been on an abnormal diet during the 28 days prior to Period I dosing.
  • Volunteers who report an intolerance of direct venipuncture.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    1

    Drug: Fexofenadine 180 mg tablets

  • Active comparator
    2

    Drug: ALLEGRA® 180 mg tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax = Maximum Observed Concentration.

    Bioequivalence based on Cmax.

    Time frame: Blood samples collected over a 48 hour period.

  2. AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)

    Bioequivalence based on AUC0-t.

    Time frame: Blood samples collected over a 48 hour period.

  3. AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.

    Bioequivalence based on AUC0-inf.

    Time frame: Blood samples collected over a 48 hour period.

07

Results

Posted Aug 4, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneFexofenadine Hydrochloride FirstAllegra® First
Started2424
Completed2424
Not completed00
Washout of 7 Days
Participant flow — Washout of 7 Days
MilestoneFexofenadine Hydrochloride FirstAllegra® First
Started2424
Completed2424
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneFexofenadine Hydrochloride FirstAllegra® First
Started2424
Completed2424
Not completed00

Outcome measures

PrimaryCmax = Maximum Observed Concentration.

Bioequivalence based on Cmax.

Time frame:
Blood samples collected over a 48 hour period.
Reported as:
Mean · ng/mL
Cmax = Maximum Observed Concentration.
ng/mLFexofenadine HydrochlorideAllegra®
Cmax = Maximum Observed Concentration.449.6 ± 216.08498.95 ± 204.3
Statistical analysis
  • Fexofenadine Hydrochloride vs Allegra® · Ratio of the t/r geometric mean x 100: 87.96 · 90% CI 80.15 to 96.53To establish bioequivalence, the mean values for the test product differ by no more than 20% from the respective mean values for the reference listed product.
PrimaryAUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)

Bioequivalence based on AUC0-t.

Time frame:
Blood samples collected over a 48 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)
ng*h/mLFexofenadine HydrochlorideAllegra®
AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)2711.8 ± 1118.22912.63 ± 1092.78
Statistical analysis
  • Fexofenadine Hydrochloride vs Allegra® · Ratio of the t/r geometric mean x 100: 91.47 · 90% CI 85.15 to 98.26To establish bioequivalence, the mean values for the test product differ by no more that 20% from the repective mean values for the reference listed product.
PrimaryAUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.

Bioequivalence based on AUC0-inf.

Time frame:
Blood samples collected over a 48 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.
ng*h/mLFexofenadine HydrochlorideAllegra®
AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.2814.79 ± 1132.183024.53 ± 1104.18
Statistical analysis
  • Fexofenadine Hydrochloride vs Allegra® · Ratio of the t/r geometric mean x 100: 91.47 · 90% CI 85.32 to 98.07To establish bioequivalence, the mean values for the test product differ by no more than 20% from the respective mean values for the reference listed product.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Fexofenadine Hydrochloride FirstAllegra® FirstTotal
<=18 years000
Between 18 and 65 years242448
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Fexofenadine Hydrochloride FirstAllegra® FirstTotal
Female61117
Male181331
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fexofenadine Hydrochloride FirstAllegra® FirstTotal
American Indian101
White222446
Hispanic101
Region of Enrollment
Region of Enrollment(participants)Fexofenadine Hydrochloride FirstAllegra® FirstTotal
United States242448
08

Study locations

1 site
  • PRACS Institute, Ltd.
    Fargo, North Dakota 58102, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Mar 2002 and a completion of Mar 2002. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 7 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2009
First posted
Feb 3, 2009
Start
Mar 2002
Primary completionActual
Mar 2002
CompletionActual
Mar 2002
Results first posted
Aug 4, 2009
Last update
Aug 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00835276
First posted
Feb 3, 2009
Start date
Mar 2002
Primary completion
Mar 2002
Completion
Mar 2002
Results posted
Aug 4, 2009
Last update
Aug 20, 2009

Study contacts

James D Carlson, Pharm. D.
principal investigator · PRACS Institute, Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexofenadine

Start the discussion